What Makes an Effective PROTAC? Unlocking Drug-Resistant Pathways Through Warhead, Linker, and Anchor Modifications

Research Paper Description;
This research investigates the structural design of PROTACs (Proteolysis-Targeting Chimeras), a novel class of therapeutic molecules that induce targeted protein degradation by recruiting specific E3 ubiquitin ligases to disease-related proteins. The study explores how variations in the three key components of PROTACs , the warhead (target-binding ligand), the linker (spacer), and the anchor (E3 ligase ligand) , influence their ability to reach and degrade proteins that are typically inaccessible to traditional small molecule drugs. By analyzing five theoretically designed PROTAC candidates targeting CDK9, a kinase implicated in cancer, this paper aims to highlight design strategies that optimize selectivity, binding cooperativity, and degradation efficiency. The work also emphasizes the potential of PROTACs to act as “smart drugs,” capable of bypassing limitations in conventional drug therapy by hijacking the cell’s own protein disposal system.

Research Paper done by an 11th grader from Bali, Indonesia from online school: Wolsey Hall Oxford.

License:
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
You may share and adapt it with credit, non-commercially, and under the same license. Credit must be given to the original author: Ell Siti Macpherson.